| Date | Company | Amount | Funding type | Investors | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2017-01-19 | Anavex Life Sciences (USA - NY) | $ 0.6 million | grant | Rettsyndrome.org (USA - OH) | Neurological diseases - CNS diseases | Grant |
| 2017-01-19 | Octimet Oncology (Belgium) | € 11.3 million | series A financing round | V-Bio Ventures (Belgium) Fund+ (Belgium) DROIA Oncology Ventures (Luxembourg/Belgium) OMNES Capital (France) | Cancer - Oncology | Series A financing round |
| 2017-01-19 | PCI Biotech (Norway) | capital increase | Cancer - Oncology | Capital increase | ||
| 2017-01-17 | Fibrocor Therapeutics (Canada) | $ 2.1 million | financing round | Evotec (Germany) MaRS Innovation (Canada) | Fibrotic diseases | Financing round |
| 2017-01-11 | Mirati Therapeutics (USA - CA) | $65 million | private placement | Cancer - Oncology | Private placement | |
| 2017-01-10 | Loxo Oncology (USA - CA) | $138 million | private placement | Cancer - Oncology | Private placement | |
| 2017-01-09 | Eternygen (Germany) | € 8 million | series A financing round | Evotec (Germany) Epidarex Capital (UK) EMBL Ventures (Germany) IBB Beteiligungsgesellschaft GmbH (Germany) two renowned family offices. | Metabolic diseases | Series A financing round |
| 2017-01-09 | Abivax (France) | €8.4 million | grant | Bpifrance (France) | Infectious diseases | Grant |
| 2017-01-09 | Kymab (UK) | $9 million | grant | Bill & Melinda Gates Foundation (USA) | Infectious diseases | Grant |
| 2017-01-09 | Y-mAbs Therapeutics (USA - NY) | $12 million | private placement | Cancer - Oncology | Private placement | |
| 2017-01-06 | PCI Biotech (Norway) Ultimovacs (Norway) | NOK 500,000 | grant | Innovation Norway (Norway) | Cancer - Oncology | Grant |
| 2017-01-05 | Therachon (France) | $ 40 million | series A financing round | OrbiMed (USA - NY) New Enterprise Associates (NEA) (USA - MD) Inserm Transfert Initiative (ITI) (France) Versant Ventures (USA - CA) Bpifrance (France) | Rare diseases - Genetic diseases | Series A financing round |
| 2017-01-05 | Nerre Therapeutics (UK) | £23 million | series B financing round | Fountain Healthcare Partners (Ireland) Forbion Capital Partners (The Netherlands) OrbiMed (USA - NY) Advent Life Sciences (UK) Novo A/S (Sweden) | Series B financing round | |
| 2017-01-05 | Neon Therapeutics (USA - MA) | $70 million | series B financing round | Cancer - Oncology | Series B financing round | |
| 2017-01-04 | Clovis Oncology (USA - CO) | $175 million | private placement | Cancer - Oncology | Private placement | |
| 2016-12-21 | Oryzon Genomics (Spain) | $ 0.8 million | grant | Ministry of Economy and Competitiveness, Government of Spain, FEDER Funds | Inflammatory diseases | Grant |
| 2016-12-20 | Tigenix (Belgium) | $35.65 million | IPO | Autoimmune diseases - Inflammatory diseases - Digestive diseases - Regenerative medicine | IPO | |
| 2016-12-20 | Phi Pharma (Switzerland) | CHF 3.7 million | series A financing round | undisclosed investor | Cancer - Oncology - Infectious diseases | Series A financing round |
| 2016-12-19 | Nabriva Therapeutics (Austria) | $25 million | private placement | Infectious diseases | Private placement | |
| 2016-12-16 | Soligenix (USA - NJ) | $ 5.28 million | private placement | Rare diseases | Private placement |
